The PARTNER (Placement of Aortic Transcatheter Valve Trial) has been paving the way since 2011, establishing that transcatheter aortic valve replacement (TAVR) is equally effective as surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis (AS) who are at high surgical risk. In 2019, the advantages of TAVR were extended to patients with…
Login in to view this article:
You need to be logged in to view the rest of this article. Don't have an account? Register for one below.
Subscribe
0 Comments
Oldest
Sponsored Links
